MADIA will develop a versatile and cost-effective in-vitro tool for early diagnosis of Alzheimer’s and Parkinson’s diseases. Alzheimer’s and Parkinson’s diseases, the two most common neurodegenerative disorder worldwide, are debilitating and largely untreatable conditions that are strongly linked with age.

 "MADIA does not stop and this site does not close!

MADIA has concluded its EC engaged and funded work on March 31^st 2020.

The project has successfully fulfilled its main objectives – it has entirely demonstrated the highest diagnostic potential of the proposed technology, confirming the most ambitious objectives, such as fg/ml detection capability. Most partners of the consortium are interested to upgrade further the developed technologic devices, bringing them to a pre-commercial prototype level. Formal agreements between different partners and groups of partners are being established to proceed on this route.

Stay in touch, visit our site for future updates and developments."

 - Project Coordinator – Valentin Alek Dediu - 

Click here to see more information on our NEWSLETTER!

Events

MADIA FINAL PROJECT MEETING

The MADIA Final project meeting was held on 20^th  and 21^st  February 2019 in Bologna, Italy and it has been the occasion to verify all together with the last achievements Madia related but also to thank each other for the great cooperation experienced during the (more than) 3 years’ Project and to plan fruitful collaborations in the next future!

Alzheimer’s is the most common form of dementia, affecting seven million across Europe. The global cost of dementia in 2015 was around US$ 820 billion, meaning that age-related neurodegenerative disease is one of the largest medical and societal challenges faced by our society.

Costs of dementia in 2015 (billion US$), by G7 and G20 country classification

(Source: World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.)